Denifanstat

SKU: orb1308311

Description

Denifanstat

Research Area

Metabolism Research

Key Properties

• CAS Number: 1399177-37-7
• MW: 439.55
• Purity: 99.44%
• Formula: C₂₇H₂₉N₅O
• SMILES: Cc1n[nH]c(n1)-c1cc(C(=O)N2CCC(CC2)c2ccc(cc2)C#N)c(C)cc1C1CCC1
• Target: Fatty Acid Synthase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:6 mg/mL (13.65 mM);DMSO:262.5 mg/mL (597.2 mM)

Bioactivity

• Target IC50:
  FASN:0.072 μM (EC50)|FASN:0.052 μM
• In Vivo:
  METHODS: To assay antitumor activity in vivo, Denifanstat (100 mg/kg, 30% PEG400) was administered by gavage to SCID mice bearing PC-3M/HOXB13KD xenografts once daily for six weeks. RESULTS: Five weeks after inoculation, HOXB13-KD mice showed significant metastasis in IVIS, which was completely alleviated by Denifanstat treatment.Denifanstat treatment significantly prolonged metastasis-free survival in both control and HOXB13-KD mice.
• In Vitro:
  METHODS: MDA-MD-231 and MDA-MB-231-BR cells were treated with Denifanstat (1-10.3 µM) for 6-30 h. Cell migration was detected by wound healing assay. RESULTS: Cell migration was inhibited in MDA-MB-231-BR cells but not in parental MDA-MD-231 cells in a dose-dependent manner.

Storage & Handling

• Storage: keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ASC40, ASC-40, ASC 40, COVID-19, Denifanstat, Inhibitor, FASN-IN-2, FASN, Fatty Acid Synthase (FASN), Fatty Acid Synthase, FattyAcidSynthase, inhibit, SARS-CoV2, spike, protein, TVB 2640, TVB2640, TVB-2640

Compound Identifiers

PubChem CID

66548316